OTC Markets OTCPK - Delayed Quote USD

Orion Oyj (ORINY)

28.19

0.00

(0.00%)

As of April 16 at 4:00:00 PM EDT. Market Open.

Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

ORION CORPORATION PRESS RELEASE 15 April 2025 at 10.00 EEST Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded Orion Corporation announced in a press release on 10 March 2025 that the company is establishing a new research and development centre in Cambridge, UK with a focus on biological medicines. As the company's plan is to develop biological and large-molecule therapies in Cambridge, a statutory negotiation process commenced on 7 March 2025 in accordance with th

GlobeNewswire 2 days ago

ORINF

ORINY
0.00%
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence It has come to the attention of Orion Corporation that the Helsinki Court of Appeal has sentenced Ari Lehtoranta, a member of Orion’s Board of Directors, to a fine for a securities market information offence. The judgment of the Co

GlobeNewswire 7 days ago

ORINF

ORINY
0.00%
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at approximately 12.00 noon EEST. The release and related presentation material will be available on the company’s website at www.orionpharma.com/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and med

GlobeNewswire 8 days ago

ORINF

ORINY
0.00%
Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE3 APRIL 2025 at 16.25 EEST Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chairman. The compositions of the Board committees were decided to be as follows: Personnel and Remuneration Committee

GlobeNewswire 14 days ago

ORINF

ORINY
0.00%
Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025

ORION CORPORATION STOCK EXCHANGE RELEASE – DECISIONS OF GENERAL MEETING3 APRIL 2025 at 16.20 EEST Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025 At the Annual General Meeting of Orion Corporation held today, the following decisions were made: A dividend of EUR 1.64 per share was confirmed to be paid. The dividend is paid in two instalments. The proposals concerning the election and remuneration of the Board of Directors, the election and remuneration of the auditor

GlobeNewswire 14 days ago

ORINF

ORINY
0.00%
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS21 March 2025 at 15.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 20 March 2025 below five (5) per ce

GlobeNewswire 27 days ago

ORINF

ORINY
0.00%
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030

ORION CORPORATION PRESS RELEASE 21 MARCH 2025 at 13:00 EET Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, pharmaceutical companies invested more than EUR 460 million in Finland, half of which went into R&D and the other half into production. On Friday 21 March, representatives of the pharmaceutical industry submitted the sector’s value proposition to Riikka Purra, the Minister of Finance. The industry wants to play its part in c

GlobeNewswire 27 days ago

ORINF

ORINY
0.00%
Orion Group Financial Statement documents 2024 and Remuneration Report published

ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT11 MARCH 2025 at 11.15 EET Orion Group Financial Statement documents 2024 and Remuneration Report published Orion Group's Financial Statement documents for 2024 have been published. The documents are available in Finnish and English on the Company's website at https://www.orionpharma.com/annual-reports and are attached to this release. Financial Statement documents include the company’s Financial Statements, the Report by the Boar

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Hao Pan

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Hao PanPositi

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Satu Ahomäki

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Satu Aho

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Juhani Kankaanpää

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Juh

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Julia Macharey

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Julia Macharey Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Julia

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Niclas Lindstedt

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Nicl

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – René Lindell

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – René Lindell Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: René Lin

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Liisa Hurme

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa Hur

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Outi Vaarala

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Outi Vaa

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Managers’ transactions – Olli Huotari

ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers’ transactions – Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Olli Huo

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2025 at 19.00 EET Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. T

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku

ORION CORPORATION PRESS RELEASE 10 March 2025 at 11.45 EET Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku Orion Corporation today announced that it is establishing a new research & development centre in Cambridge, UK during 2025 to accelerate its global growth strategy and the development of innovative medicines. The new centre will focus on the development of new biological and large-molecule therapies

GlobeNewswire last month

ORINF

ORINY
0.00%
Orion and Aiforia extend collaboration to preclinical study evaluations

ORION CORPORATION PRESS RELEASE 5 MARCH 2025 at 9.00 EET Orion and Aiforia extend collaboration to preclinical study evaluations Orion Corporation (“Orion”) and Aiforia Technologies Plc (“Aiforia”), a Finnish medical software company, today announced the extension of their collaboration to include the use of Aiforia's software solution for preclinical study evaluations. This collaboration will involve implementing the Aiforia®Studies module within Orion's preclinical histology processes, as well

GlobeNewswire last month

ORINF

ORINY
0.00%

Performance Overview

Return	ORINY	OMX Helsinki_PI (^OMXHPI)
YTD	+30.30%	0.00%
1-Year	+58.90%	0.00%
3-Year	+35.23%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Orion Oyj (ORINY)

Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

Orion Corporation: Organising meeting of the Board of Directors

Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030

Orion Group Financial Statement documents 2024 and Remuneration Report published

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation: Managers’ transactions – Julia Macharey

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation: Managers’ transactions – René Lindell

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation: Managers’ transactions – Olli Huotari

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku

Orion and Aiforia extend collaboration to preclinical study evaluations

Performance Overview